---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-006430"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2025-02-19T23:59:59+00:00"
generated_at: "2026-05-26T10:24:51.795591+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cumberland gets NMPA approval in China for Vibativ; exclusive deal with SciClone

## Summary
- Vibativ (telavancin) approved by China's NMPA for hospital-acquired pneumonia, ventilator-associated pneumonia, and complicated skin infections.
- SciClone granted exclusive rights to register, promote, and distribute Vibativ in China.
- Companies plan to launch Vibativ in China later in 2025.
- Vibativ is a once-daily IV antibiotic designed to treat multidrug-resistant Gram-positive bacteria.

## SEC filing metadata
- accession: 0001628280-25-006430
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2025-02-19T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000162828025006430/0001628280-25-006430-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000162828025006430/cpix-20250219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-006430
- JSON: https://secwatch.observer/filing/0001628280-25-006430.json
- Plain text: https://secwatch.observer/filing/0001628280-25-006430.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.